Top

Published in:

01-04-2022 | Dapagliflozin | Unknown

Dapagliflozin associated with higher risk of ketoacidosis in T2DM patients

Published in: Reactions Weekly | Issue 1/2022

Excerpt

Compared with insulin, dipeptidyl peptidase-4 (DPP-4) inhibitors, dapagliflozin is associated with a greater rate of ketoacidosis in patients with type-2 diabetes mellitus (T2DM), according to findings published in Pharmaceuticals. …

The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study Pharmaceuticals : 28 Mar 2022. Available from: URL: https://doi.org/10.3390/ph15030286

Title: Dapagliflozin associated with higher risk of ketoacidosis in T2DM patients
Publication date: 01-04-2022
Publisher: Springer International Publishing
Keywords: Dapagliflozin
Insulins
Ketoacidosis
Insulins
Diabetes
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-12358-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dapagliflozin associated with higher risk of ketoacidosis in T2DM patients

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Levetiracetam

Tozinameran

Prednisolone

Antineoplastics

Oxaliplatin

Isotretinoin